BronchoTech
GLOBAL MEDTECH PLATFORM

Transforming pulmonary care.

A scalable medical technology platform addressing over 600 million patients worldwide. The Resector Balloon is reshaping how airway disease is treated — across every hospital, every geography.

BronchoTech Resector Balloon — the flagship interventional pulmonology device
THE PROBLEM

Pulmonary disease is a global crisis — and current care cannot keep up.

Over 600 million patients globally live with chronic airway conditions. Treatment options remain limited, invasive, or unaffordable for the majority of those who need them.

The economic burden exceeds trillions of dollars annually across healthcare systems, yet innovation in interventional pulmonology has stagnated for decades.

Hospitals face a widening gap — rising demand, aging populations, and no scalable answer for the majority of airway disease presentations.

Anatomical illustration of human lungs with diseased tissue (Servier Medical Art, CC BY 4.0)
600M+
Patients affected worldwide
$1T+
Annual economic burden
1,000+
Cases supporting our evidence base
THE TECHNOLOGY

Meet the Resector Balloon.

A minimally invasive platform designed to treat airway disease with precision, safety, and scalability — engineered for any hospital, any geography.

BronchoTech Resector Balloon — full product render with control handle
Illustration of the human bronchial tree — the anatomical target of the Resector Balloon (Servier Medical Art, CC BY 4.0)
Airway anatomy. The Resector Balloon is designed to navigate the bronchial tree with precision.

Clinically validated

1,000+ patient cases supporting outcomes and safety profile.

Minimally invasive

Short procedure times, faster recovery, outpatient-feasible.

Globally deployable

Designed for both high-volume markets and emerging healthcare systems.

THE MARKET

A category-defining opportunity.

The global market for interventional pulmonology exceeds hundreds of billions, driven by aging populations, rising smoking-attributable disease in emerging markets, and an enormous unmet need for outpatient-feasible airway interventions.

600M+
Addressable patient pool
$120B+
Serviceable market by 2032
15%+
CAGR in interventional pulmonology
70%
Patients currently underserved
GLOBAL INFRASTRUCTURE

Two hubs. One global platform.

BronchoTech operates through a deliberately structured dual-hub model, giving direct access to two of the world's most strategically important medtech corridors.

PRIMARY HUB · ASIA

Shanghai

Positioned for volume and rapid scalability across China and the broader Asian market. Our engine for clinical throughput, manufacturing proximity, and physician training at scale.

4.7B
Population reach
2027
Launch
SECONDARY HUB · EUROPE & MENA

Istanbul

A gateway into European and Middle Eastern healthcare systems. Drives medical tourism access, regulatory pathways into developed markets, and regional partnerships.

2.1B
Population reach
2027
Launch
THE TEN-YEAR PLAN

A path to global category leadership.

Three phases. Ten years. One objective — make BronchoTech the global standard in pulmonary intervention.

  1. 2027–2029
    Phase 1

    Foundation

    • Launch of Shanghai & Istanbul hubs
    • First treatments and physician training programs
    • Initial strategic partnerships

    Clinical validation + early revenue

  2. 2030–2033
    Phase 2

    Scale

    • Expansion across Asia & Europe
    • Physician certification pipeline
    • Standardization of procedural protocols

    Platform-level recognition

  3. 2034–2037
    Phase 3

    Global Expansion

    • US market entry
    • Global adoption across healthcare systems
    • Full commercial scale

    Market leadership

GET IN TOUCH

Partner with us on the future of pulmonary care.

Whether you are an investor, a clinical partner, a distributor, or a health system considering integration, we'd like to talk.

DISCLOSURES & IMPORTANT INFORMATION